Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Victor Knopov

Premium

Regulus Therapeutics has named Victor Knopov its vice president of pharmaceutical development.

He most recently served as director of chemistry manufacturing control at Nitto Denko Technical. Before that, Knopov was COO at Diversified Bio-Medics and has previously worked as a consultant for Marina Biotech.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.